|
1
|
Viale A, Pettazzoni P, Lyssiotis CA, Ying
H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V,
et al: Oncogene ablation-resistant pancreatic cancer cells depend
on mitochondrial function. Nature. 514:628–632. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Antal CE, Hudson AM, Kang E, Zanca C,
Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari
FB, et al: Cancer-associated protein kinase C mutations reveal
kinase’s role as tumor suppressor. Cell. 160:489–502. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chistiakov DA and Chekhonin VP:
Extracellular vesicles shed by glioma cells: Pathogenic role and
clinical value. Tumour Biol. 35:8425–8438. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang XQ and Leung GK: Long non-coding
RNAs in glioma: Functional roles and clinical perspectives.
Neurochem Int. 77:78–85. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chautard E, Ouédraogo ZG, Biau J and
Verrelle P: Role of Akt in human malignant glioma: From oncogenesis
to tumor aggressiveness. J Neurooncol. 117:205–215. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Katsetos CD, Reginato MJ, Baas PW,
D’Agostino L, Legido A, Tuszyn Ski JA, Dráberová E and Dráber P:
Emerging microtubule targets in glioma therapy. Semin Pediatr
Neurol. 22:49–72. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Awad AJ, Burns TC, Zhang Y and Abounader
R: Targeting MET for glioma therapy. Neurosurg Focus. 37:E102014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huse JT and Aldape KD: The evolving role
of molecular markers in the diagnosis and management of diffuse
glioma. Clin Cancer Res. 20:5601–5611. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bours V, Franzoso G, Azarenko V, Park S,
Kanno T, Brown K and Siebenlist U: The oncoprotein Bcl-3 directly
transactivates through kappa B motifs via association with
DNA-binding p50B homodimers. Cell. 72:729–739. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cogswell PC, Guttridge DC, Funkhouser WK
and Baldwin AS Jr: Selective activation of NF-kappa B subunits in
human breast cancer: Potential roles for NF-kappa B2/p52 and for
Bcl-3. Oncogene. 19:1123–1131. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Choi HJ, Lee JM, Kim H, Nam HJ, Shin HJ,
Kim D, Ko E, Noh DY, Kim KI, Kim JH, et al: Bcl3-dependent
stabilization of CtBP1 is crucial for the inhibition of apoptosis
and tumor progression in breast cancer. Biochem Biophys Res Commun.
400:396–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thornburg NJ, Pathmanathan R and
Raab-Traub N: Activation of nuclear factor-kappaB p50
homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res.
63:8293–8301. 2003.PubMed/NCBI
|
|
13
|
Pallares J, Martínez-Guitarte JL, Dolcet
X, Llobet D, Rue M, Palacios J, Prat J and Matias-Guiu X:
Abnormalities in the NF-kappaB family and related proteins in
endometrial carcinoma. J Pathol. 204:569–577. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tu K, Liu Z, Yao B, Xue Y, Xu M, Dou C,
Yin G and Wang J: BCL-3 promotes the tumor growth of hepatocellular
carcinoma by regulating cell proliferation and the cell cycle
through cyclin D1. Oncol Rep. 35:2382–2390. 2016.PubMed/NCBI
|
|
15
|
Puvvada SD, Funkhouser WK, Greene K, Deal
A, Chu H, Baldwin AS, Tepper JE and O’Neil BH: NF-κB and Bcl-3
activation are prognostic in metastatic colorectal cancer.
Oncology. 78:181–188. 2010. View Article : Google Scholar :
|
|
16
|
Liu Z, Jiang Y, Hou Y, Hu Y, Cao X, Tao Y,
Xu C, Liu S, Wang S, Wang L, et al: The IκB family member Bcl-3
stabilizes c-Myc in colorectal cancer. J Mol Cell Biol. 5:280–282.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maldonado V, Espinosa M, Pruefer F, Patiño
N, Ceballos-Canciono G, Urzua U, Juretic N and Melendez-Zajgla J:
Gene regulation by BCL3 in a cervical cancer cell line. Folia Biol
(Praha). 56:183–193. 2010.
|
|
18
|
Mansour NM, Bernal GM, Wu L, Crawley CD,
Cahill KE, Voce DJ, Balyasnikova IV, Zhang W, Spretz R, Nunez L, et
al: Decoy receptor DcR1 is induced in a p50/Bcl3-dependent manner
and attenuates the efficacy of temozolomide. Cancer Res.
75:2039–2048. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pessôa IA, Sagica FE, Anselmo NP, Brito JR
and de Oliveira EH: IDH1 and IDH2 mutations in different histologic
subtypes and WHO grading gliomas in a sample from Northern Brazil.
Genet Mol Res. 14:6533–6542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tu K, Li J, Verma VK, Liu C, Billadeau DD,
Lamprecht G, Xiang X, Guo L, Dhanasekaran R, Roberts LR, et al:
Vasodilator-stimulated phosphoprotein promotes activation of
hepatic stellate cells by regulating Rab11-dependent plasma
membrane targeting of transforming growth factor beta receptors.
Hepatology. 61:361–374. 2015. View Article : Google Scholar
|
|
21
|
Cipriano R, Miskimen KL, Bryson BL, Foy
CR, Bartel CA and Jackson MW: Conserved oncogenic behavior of the
FAM83 family regulates MAPK signaling in human cancer. Mol Cancer
Res. 12:1156–1165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li H, Liu YW, Wang H, Zhou Q, Li JJ, Annie
H, Qi ST and Lu YT: MiR-519a functions as a tumor suppressor in
glioma by targeting the oncogenic STAT3 pathway. J Neurooncol.
128:35–45. 2016. View Article : Google Scholar
|
|
23
|
Hartel I, Ronellenfitsch M, Wanka C,
Wolking S, Steinbach JP and Rieger J: Activation of AMP-activated
kinase modulates sensitivity of glioma cells against epidermal
growth factor receptor inhibition. Int J Oncol. 49:173–180.
2016.PubMed/NCBI
|
|
24
|
Foster KA, Jane EP, Premkumar DR, Morales
A and Pollack IF: NVP-BKM120 potentiates apoptosis in tumor
necrosis factor-related apoptosis-inducing ligand-resistant glioma
cell lines via upregulation of Noxa and death receptor 5. Int J
Oncol. 47:506–516. 2015.PubMed/NCBI
|
|
25
|
Wang H, Wang Y, Bao Z, Zhang C, Liu Y, Cai
J and Jiang C: Hypomethylated Rab27b is a progression-associated
prognostic biomarker of glioma regulating MMP-9 to promote
invasion. Oncol Rep. 34:1503–1509. 2015.PubMed/NCBI
|
|
26
|
Guan Y, Yao H, Zheng Z, Qiu G and Sun K:
MiR-125b targets BCL3 and suppresses ovarian cancer proliferation.
Int J Cancer. 128:2274–2283. 2011. View Article : Google Scholar
|
|
27
|
Wu ZL, Song YQ, Shi YF and Zhu J: High
nuclear expression of STAT3 is associated with unfavorable
prognosis in diffuse large B-cell lymphoma. J Hematol Oncol.
4:312011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Y, Wang J, Wang X, Liu X, Li H, Lv Q,
Zhu J, Wei B and Tang Y: STAT3, a poor survival predicator, is
associated with lymph node metastasis from breast cancer. J Breast
Cancer. 16:40–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Takemoto S, Ushijima K, Kawano K,
Yamaguchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Ijichi M,
Kakuma T, et al: Expression of activated signal transducer and
activator of transcription-3 predicts poor prognosis in cervical
squamous-cell carcinoma. Br J Cancer. 101:967–972. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brantley EC and Benveniste EN: Signal
transducer and activator of transcription-3: A molecular hub for
signaling pathways in gliomas. Mol Cancer Res. 6:675–684. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Iwamaru A, Szymanski S, Iwado E, Aoki H,
Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, et al: A
novel inhibitor of the STAT3 pathway induces apoptosis in malignant
glioma cells both in vitro and in vivo. Oncogene. 26:2435–2444.
2007. View Article : Google Scholar
|
